Program Overview
Join us for a conversation with two of the GT VentureLab founders to hear their stories on the development of their products and businesses and the role the GT VentureLab played in that development.
Fixd is headquartered in Atlanta and founded by John Gattuso, Julian Knight and Frederick Grimm, “3 Georgia Tech graduates who were sick of seeing friends and family get ripped off at the car repair shop.” Fixd is a sensor that instantly decodes your car’s check engine light and translates more than 7000 error codes into plain English to help you understand the severity of the problem and instructions for what to do.
Fixd was ranked #11 on Deloitte’s 2020 North America Technology Fast 500 company list and in the last 3 years, they experienced almost 18,000% growth in revenue, selling more than 2 million devices at $59 each.
Presented by: John Gattuso, Chief Executive Officer of FIXD. John directs and oversees the overall growth and strategy of the company. Prior to FIXD, John was a mechanical engineering co-op at GE Aviation and he holds a bachelor’s degree in mechanical engineering from the Georgia Institute of Technology.
EyeGage is a drug screening technology that applies eye-analysis techniques to individuals under the influence of drugs and alcohol to help prevent fatal accidents. Dr. Lavonda Brown, EyeGage’s founder has always been fascinated with eyes and what they can tell us. EyeGage employs AI recognition and analysis algorithms that can be deployed on an iPhone device or computing apparatus with an embedded camera.
EyeGage recently launched its crowdfunding campaign,
“Getting You Home Safely with the Blink of an Eye,” to raise $100,000. The crowdfunding campaign will bring the EyeGage product to market, focusing on several areas that include research and data collection, algorithm development, and five new mobile app features.
Presented by: Dr. LaVonda Brown has an MS and PhD in Electrical and Computer Engineering from Georgia Tech, as well as an MBA from the Scheller College of Business. Her expertise lies in the areas of artificial intelligence (AI) and eye-analysis technologies. She has developed a robotic engagement model based on user eye gaze and pupil size (dilation and constriction). Dr. Brown has also developed an eye-analysis system to validate eye tracking as a viable biomarker for mild cognitive impairment (MCI) and early-onset Alzheimer’s Disease (AD). Over the past decade, the robotic engagement model and eye-analysis software has been published, patented, and licensed for commercial use. After living with a loved one with an alcohol addiction, Dr. Brown has now applied the aforementioned eye-analysis techniques to individuals battling substance abuse.